Reminder: BioAge Investors Facing Pending Class Action Lawsuit
Investors who have stakes in BioAge are reminded of an impending class-action lawsuit with a lead plaintiff deadline of March 10, 2025. The lawsuit asserts claims against BioAge, a clinical-stage biotechnology company, for alleged violations of federal securities laws. Shareholders who purchased BioAge securities between August 11, 2021, and November 15, 2021, are encouraged to participate in the lawsuit and ensure their rights are protected.
The class-action lawsuit alleges that BioAge made misleading statements during the specified time frame regarding the company’s business, operations, and prospects. It is claimed that BioAge failed to disclose key information to investors, including the true state of its lead product candidate, BGE-117. The lawsuit further alleges that BioAge’s statements about the prospects of BGE-117 were materially false and misleading, causing harm to investors who purchased securities during the relevant period.
Investors who wish to serve as the lead plaintiff in the class-action lawsuit are required to meet certain criteria and must file a motion with the court by March 10, 2025. The lead plaintiff will direct the litigation and represent the interests of all shareholders involved in the lawsuit. It is important for affected investors to take action promptly to ensure they are included in the lawsuit and have their voices heard.
BioAge investors are encouraged to seek legal counsel and explore their options for participation in the class-action lawsuit. By coming forward and participating in the litigation, investors can seek to recover potential losses incurred as a result of alleged securities law violations by BioAge. Taking proactive steps to protect their rights as shareholders is crucial for affected investors seeking recourse for any harm caused by the alleged misconduct of BioAge.
In conclusion, BioAge investors should be aware of the pending class-action lawsuit against the company and the upcoming lead plaintiff deadline of March 10, 2025. By taking action and participating in the lawsuit, shareholders can work to hold BioAge accountable for alleged violations of federal securities laws and seek potential recovery for any losses incurred. Seeking legal counsel and filing a motion to serve as lead plaintiff are important steps for investors looking to protect their interests and seek justice in the ongoing litigation against BioAge.
